Clinical study of a 125I particle-integrated esophageal covered stent and hyperbaric oxygen in the treatment of advanced esophageal cancer.

Y. Ren,Jianxin Xie,Guoliang Li,Jian-biao Shang,Qizhou Zhang
DOI: https://doi.org/10.17235/reed.2020.7377/2020
2020-12-02
Abstract:OBJECTIVE This study aimed to investigate the clinical efficacy and feasibility of the treatment of advanced esophageal cancer with a combination of a 125I particle-integrated esophageal covered stent and hyperbaric oxygen. METHODS 45 patients with advanced esophageal cancer were enrolled and were randomly divided into two groups: a treatment group and a control group. Patients in the treatment group were treated with a 125I particle-integrated esophageal covered stent and hyperbaric oxygen, while patients in the control group were treated with a 125I particle-integrated esophageal covered stent, and the clinical effects and long-term survival time of the two groups were observed. RESULTS In the treatment group, the complete remission (CR) rate and partial remission (PR) rate of local lesions were 19.2% and 61.5% respectively, and the total effective rate was 80.7%. In the control group, the CR rate and PR rate of local lesions were 10.5% and 52.6%, respectively, and the total effective rate was 63.1%. The total effective rate was higher in the treatment group than in the control group, and the difference was statistically significant (P < 0.05). CONCLUSION The combination of a 125I particle-integrated esophageal covered stent and hyperbaric oxygen shows good short- and long-term efficacy in the treatment of advanced esophageal cancer.
Medicine
What problem does this paper attempt to address?